Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Income (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Net Income for 4 consecutive years, with -$20.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 35.02% to -$20.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$75.1 million, a 31.13% decrease, with the full-year FY2024 number at -$60.9 million, down 27.88% from a year prior.
  • Net Income was -$20.8 million for Q3 2025 at Orchestra BioMed Holdings, down from -$19.4 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$813415.0 in Q3 2022 to a low of -$20.8 million in Q3 2025.
  • A 4-year average of -$12.9 million and a median of -$13.4 million in 2024 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 1573.07% in 2023, then dropped 13.35% in 2024.
  • Orchestra BioMed Holdings' Net Income stood at -$9.8 million in 2022, then dropped by 26.99% to -$12.5 million in 2023, then fell by 29.44% to -$16.2 million in 2024, then fell by 28.93% to -$20.8 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Net Income are -$20.8 million (Q3 2025), -$19.4 million (Q2 2025), and -$18.8 million (Q1 2025).